(Q46245352)

English

Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

single-nucleotide polymorphism

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Benoit Beuselinck

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Jean-Jacques Patard

18

object named as

Jean-Jacques Patard

1 reference

Europe PubMed Central

20 December 2017

Diether Lambrechts

2

object named as

Diether Lambrechts

1 reference

Europe PubMed Central

20 December 2017

Patrick Schöffski

15

object named as

Patrick Schöffski

1 reference

Europe PubMed Central

20 December 2017

author name string

Thomas Van Brussel

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Pascal Wolter

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Nina Cardinaels

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Steven Joniau

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Evelyne Lerut

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Alexandra Karadimou

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Gabrielle Couchy

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Philippe Sebe

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Alain Ravaud

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Marc Zerbib

12

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Armelle Caty

13

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Robert Paridaens

14

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Virginie Verkarre

16

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Julien Berger

17

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Jessica Zucman-Rossi

19

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Stéphane Oudard

20

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 May 2014

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Acta Oncologica

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

53

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

1413-1422

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

ABC of oral bioavailability: transporters as gatekeepers in the gut.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.918276

21 January 2018

Identifiers

10.3109/0284186X.2014.918276

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/24874929

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46245352&oldid=2102101549"